Benitec Biopharma logo

Benitec BiopharmaNASDAQ: BNTC

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

24 June 2014

Next earnings report:

13 February 2025

Last dividends:

N/A

Next dividends:

N/A
$247.49 M
-2%vs. 3y high
56%vs. sector
-vs. 3y high
-vs. sector
-90%vs. 3y high
75%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Wed, 20 Nov 2024 21:00:09 GMT
$10.66+$0.86(+8.77%)

Dividend

No data over the past 3 years

Analysts recommendations

Institutional Ownership

BNTC Latest News

Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update
globenewswire.com14 November 2024 Sentiment: POSITIVE

-Positive 270-day Interim Clinical Study Data for the First Subject and Positive 180-day Interim Clinical Study Data for the Second Subject Treated with the Low-Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in October as a Late-Breaking Oral Presentation at the 29 th Annual Congress of the World Muscle Society-

Benitec Biopharma: OPMD Program Continues To Advance With Catalysts
seekingalpha.com17 October 2024 Sentiment: POSITIVE

Benitec Biopharma Inc.'s BB-301 showed positive interim results in treating OPMD, allowing for higher dosing in 2025 and a potential late-stage trial in 2026. BB-301 demonstrated significant improvements in swallowing function and reduced pharyngeal residue, with no serious adverse events reported in the phase 1b/2a study. Financially, Benitec Biopharma is well-positioned with $50.9 million in cash, sufficient to fund operations through 2025, thanks to a $40 million PIPE financing.

Benitec Biopharma Announces Updated Investor Webcast Information
globenewswire.com14 October 2024 Sentiment: POSITIVE

-Management plans to host an investor webcast on October 14 th at 8:30 am EDT to provide an update for the BB-301 Phase 1b/2a Clinical Study, details below-

Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle Society
globenewswire.com12 October 2024 Sentiment: POSITIVE

-Subject 1 and Subject 2 experienced durable, clinically meaningful improvements in swallowing at 9-months and 6-months post-BB-301 treatment, respectively, with Subject 2 achieving a Sydney Swallow Questionnaire Score Representative of Clinically Normal Swallowing-

Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update
globenewswire.com26 September 2024 Sentiment: POSITIVE

-Positive 90-day and 180-day Interim Clinical Trial Data for the First Oculopharyngeal Muscular Dystrophy (OPMD) Subject Dosed with the Low-Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in April and July-

Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phase 1b/2a Study
globenewswire.com15 July 2024 Sentiment: POSITIVE

-The post-dose average values for Total Pharyngeal Residue (i.e., the amount of solid food or liquid material remaining in the pharynx after the first swallow) remained meaningfully reduced at the 180-day post-dose assessment following the administration of the low dose of gene therapy BB-301 as compared to the pre-dose average values recorded for Subject 1 during the OPMD Natural History Study-

Benitec Biopharma to Present at the OPMD International Conference
GlobeNewsWire08 May 2023 Sentiment: POSITIVE

HAYWARD, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced that Jerel A.

What type of business is Benitec Biopharma?

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California.

What sector is Benitec Biopharma in?

Benitec Biopharma is in the Healthcare sector

What industry is Benitec Biopharma in?

Benitec Biopharma is in the Biotechnology industry

What country is Benitec Biopharma from?

Benitec Biopharma is headquartered in United States

When did Benitec Biopharma go public?

Benitec Biopharma initial public offering (IPO) was on 24 June 2014

What is Benitec Biopharma website?

https://benitec.com

Is Benitec Biopharma in the S&P 500?

No, Benitec Biopharma is not included in the S&P 500 index

Is Benitec Biopharma in the NASDAQ 100?

No, Benitec Biopharma is not included in the NASDAQ 100 index

Is Benitec Biopharma in the Dow Jones?

No, Benitec Biopharma is not included in the Dow Jones index

When was Benitec Biopharma the previous earnings report?

No data

When does Benitec Biopharma earnings report?

The next expected earnings date for Benitec Biopharma is 13 February 2025